Bousser, M., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K., . . . Rothwell, P. M. (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: The prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular diseases, 27(5), . https://doi.org/10.1159/000212671
Chicago-Zitierstil (17. Ausg.)Bousser, Marie-Germaine, P. Amarenco, A. Chamorro, M. Fisher, I. Ford, K. Fox, Michael G. Hennerici, H. P. Mattle, und P. M. Rothwell. "Rationale and Design of a Randomized, Double-blind, Parallel-group Study of Terutroban 30 Mg/day Versus Aspirin 100 Mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study." Cerebrovascular Diseases 27, no. 5 (2009). https://doi.org/10.1159/000212671.
MLA-Zitierstil (9. Ausg.)Bousser, Marie-Germaine, et al. "Rationale and Design of a Randomized, Double-blind, Parallel-group Study of Terutroban 30 Mg/day Versus Aspirin 100 Mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study." Cerebrovascular Diseases, vol. 27, no. 5, 2009, https://doi.org/10.1159/000212671.